CASMI

Ignite application deadline fast approaching

ignite

CASMI and the the UCLH Biomedical Research Centre are delighted to announce the second round of Ignite: A Medical Innovation Summit.   Ignite is an immersive and challenging experience that will position a small cohort of leaders to drive change in medical innovation. By combining debate sessions, networking and immersive experiences in aligned organisations, [...]

January 26, 2018 eibhlin mullarney CASMI News 0

Accelerating access to medical innovation joint FORUM

Accelerating access to medical innovation

The Academy of Medical Sciences published the report of a joint FORUM meeting with CASMI, the Medical Research Council and the National Institute for Health Research on ‘Accelerating access to medical innovation: a research agenda for innovation science’. In summer 2017, the Academy of Medical Sciences, in partnership with CASMI, [...]

January 25, 2018 eibhlin mullarney CASMI News 0

Is Precision Medicine The Future of Healthcare?

CASMI_Brandmark_Positive

CASMI is pleased to announce that Professor Richard Barker has written a new article, published in Future Medicine, entitled ‘Is precision medicine the future of healthcare?’ The article discusses issues around definition of precision medicine, its barriers and enablers, how science can impact, and the importance of stakeholder buy-in. Click here to [...]

November 28, 2017 Maeve Waite CASMI News 0

How much do we value our good health?

reformatted-slider-graphic-101 1

Last week saw coverage by the media of NICE recommendation of two new drugs to treat breast cancer – palbociclib and ribociclib. These are a new class of small molecule drugs, which inhibit DNA synthesis and hence inhibit tumour growth. Both are tablets, and are indicated for use in previously [...]

November 27, 2017 Maeve Waite CASMI Views 0

Accelerated Access Review: Government Response

accelerated-access-2

The Accelerated Access Review set out a vision for how to deliver promising technologies to patients more quickly and more cheaply. On Friday 3rd November 2017, the Government responded to the review and accepted its recommendations. CASMI co-founder Professor Richard Barker commented, “As a major contributor to the AAR, we are delighted [...]

November 6, 2017 Maeve Waite CASMI News 0

Cancer drug funding decisions in Scotland: Impact of new end-of-life, orphan and ultra-orphan processes

CASMI_Brandmark_Positive

CASMI have recently published a new paper entitled Cancer drug funding decisions in Scotland: Impact of new end-of-life, orphan and ultra-orphan processes, in BMC Health Services Research. The paper was written by Dr Liz Morrell and Dr Richard Barker, in collaboration with co-authors from the Health Economics Research Centre and the Health Experiences Institute in [...]

September 18, 2017 Maeve Waite CASMI News 0

What else did the Cancer Drugs Fund do for us? Real-world data?

reformatted-slider-graphic-101 1

The Cancer Drugs Fund (CDF) in England – in its original incarnation between October 2010 and April 2016 – was a ring-fenced fund to provide access to cancer drugs not routinely funded by the NHS. Following reform during 2016, the CDF now offers a managed access option for cancer drugs [...]

September 4, 2017 Maeve Waite CASMI Views 0

Convergent evolution: cancer drug access in England and Scotland

reformatted-slider-graphic-101 1

The National Institute for Health and Care Excellence (NICE) in England, and the Scottish Medicines Consortium (SMC) in Scotland, face the same challenge of making drug funding recommendations that are fair to all users of the NHS and acceptable to society. Health technology appraisal is a devolved responsibility, so it [...]

August 21, 2017 Maeve Waite CASMI Views 0

NHS England and NICE changes to evaluation of drugs for rare conditions

reformatted-slider-graphic-101 1

In March this year, NICE’s board agreed a proposal to introduce Quality-Adjusted Life Years (QALYs) as the measure of value for Highly Specialised Technologies (HST – products to treat very rare conditions), with a limit of £100 000 per QALY, below which the treatment would automatically be funded.  In response [...]

June 20, 2017 Maeve Waite CASMI Views 0

Contrasting fortunes of immunotherapy drugs in first-line treatment of lung cancer

policy and impact_slider

The pharmaceutical press were quick to express their disappointment earlier this year at a draft decision by NICE, not to fund pembrolizumab (Keytruda: MSD) for first-line treatment of metastatic non-small cell lung cancer. The Appraisal committee concluded there was such uncertainty in the evidence base that it was impossible to [...]

May 22, 2017 Maeve Waite CASMI Views 0